Company Watch

Ethypharm licenses cardio product to Ranbaxy

Our News Bureau - Mumbai

Ethypharm India announced the out-licensing and supply contract agreements with Ranbaxy for a fixed dose combination of Fenofibrate micronized 160 milligram and Atorvastatin 10 milligram. This deal comes in quick succession after a similar deal that Ethypharm had signed with Ranbaxy for out-licensing and supply of Tramadol Flashtab in May this year.

The products will be supplied from Ethypharm's manufacturing facility near Mumbai as finished and packaged formulations and marketed and distributed by Ranbaxy under their brand name Storfib Commenting on the agreement, Sanjeev I Dani, Regional Director, India and Middle East, Ranbaxy said, "Ranbaxy in India is the leader in NDDS products and a pioneer in the lipids management portfolio as well. Storfib very aptly symbolises both of these strengths and would further augment our leadership position in the cardiovascular market."